Antiphospholipid Syndrome

The answer first

Antiphospholipid Syndrome is managed with an answer-first physician approach: recognise the pattern, exclude dangerous differentials, choose investigations that change action, and deliver a sequenced management plan that accounts for multimorbidity. [1] [2]

The FRACP candidate must be able to open a long-case presentation, defend thresholds, and answer DWE vignettes without hedging. Lead with the decision, then the evidence and the trap. [1]

Clinical spectrum and red flags

Presentations range from incidental or outpatient findings to emergency decompensation. Always ask what would make this urgent today — airway, perfusion, neurological threat, metabolic crisis, infection, or bleeding. [1] [2]

Red flags force same-day action rather than elective pathways. Document them explicitly in the plan. [1]

Classification that changes management

Classify by acuity, mechanism, severity and care setting. A useful classification changes investigation choice, initial therapy, disposition or specialist referral — otherwise it is taxonomy without purpose. [1] [2]

Pathophysiology linked to bedside decisions

Mechanism matters when it predicts treatment response, complications or monitoring. Teach pathophysiology as a bridge to action, not as isolated basic science. [1] [2] [3]

Differentials and discrimination

Build a short differential that includes the common, the dangerous and the commonly missed. For each alternative, name one history clue, one examination clue and one investigation that discriminates. [1] [2]

Investigations

Order tests that change management. State what is required now, what can wait, and what is low-value or harmful. Interpret results in clinical context rather than in isolation. [1] [2]

Management — immediate then definitive

1. Stabilise threats to life and organ function. [1]
2. Start disease-specific therapy once the working diagnosis is secure enough to act. [1] [2]
3. Address complications, drug interactions and monitoring. [1] [2]
4. Plan disposition, follow-up intensity and patient education with safety-net advice. [1]

Complications and prognosis

Anticipate early and late complications. Prognosis depends on severity at presentation, speed of effective therapy, comorbidity and adherence to secondary prevention or disease-modifying treatment. [1] [2]

Special populations and multimorbidity

Adjust for pregnancy potential, frailty, CKD, liver disease, immunosuppression and polypharmacy. In older adults, goals-of-care and treatment burden can change the preferred plan even when disease-directed options remain available. [1] [2]

DCE long-case angles

Open with a one-sentence synthesis, then a prioritised problem list, then an integrated plan covering investigations, treatment, prevention and communication. Link Antiphospholipid Syndrome to cardiovascular risk, infection risk, medications and social context where relevant. [1] [2]

DCE short-case angles

Be prepared to demonstrate or discuss focused examination findings, interpret a key investigation, and counsel on risks, benefits and follow-up in plain language. [1]

Exam traps

1. Delaying urgent care because the presentation looks "stable enough". [1]
2. Treating a syndrome label without confirming mechanism. [1] [2]
3. Forgetting drug interactions and organ-function dosing. [1] [2]
4. Omitting safety-net advice and follow-up ownership. [1]
5. Quoting thresholds without knowing the source trial or guideline. [1] [2] [3]

References

1. [1]Vrotniakaite-Bajerciene K, Wang TF, Sabri E, Shorr R, et al. Recurrent VTE in patients with thrombophilia after stopping anticoagulation - A systematic review and meta-analysis Blood Adv, 2026.PMID 42448302
2. [2]Fang HS, Zhang XY, Liu XY, Chen HD, et al. Chromogenic factor X-guided warfarin monitoring in lupus anticoagulant-positive primary antiphospholipid syndrome with adrenal hemorrhage and progressive deep vein thrombosis: a case report J Med Case Rep, 2026.PMID 42437947
3. [3]Mohammadi A, Fattahi V Anesthesia in systemic lupus erythematosus: a review of key considerations and surgical challenges Perioper Med (Lond), 2026.PMID 42421133
4. [4]Esteban-Sampedro J, Martín-Portugués M, Ruiz-Irastorza G, Mellor-Pita S, et al. Impact of systemic autoimmune diseases in maternal, fetal and neonatal outcomes in Spain Rheumatology (Oxford), 2026.PMID 42421209
5. [5]Hidaka A, Kaneshige R, Nakamura S, Motoki Y, et al. Preliminary Evaluation of a Novel Lupus Anticoagulant Activity Assay Unaffected by Anticoagulants J Clin Lab Anal, 2026.PMID 42310902
6. [6]Ordieres-Ortega L, Galeano-Valle F, López-Rubio M, Alonso-Beato R, et al. Recurrent VTE During Anticoagulation: Diagnosis, Systematic Evaluation, and Management Chest, 2026.PMID 42264028
7. [7]Xi Y, Yao T, Zhang C, Zhuang T Effectiveness of safety care and clinical nursing pathway in patients undergoing cardiovascular intervention: a randomized controlled trial Perioper Med (Lond), 2026.PMID 42469924
8. [8]Marks FJ, Walters SJ, Sutton L, Jacques RM What statistical methods are more appropriate for predicting recruitment at the design stage of a randomised controlled trial? Trials, 2026.PMID 42469922
9. [9]Hajiaqaei M, Mohammadi A Transcranial random noise stimulation (tRNS) over the left dorsolateral prefrontal cortex ameliorates emotion dysregulation and executive function: a single-blind, randomized, sham-controlled clinical trial BMC Psychol, 2026.PMID 42469906
10. [10]Xu H, Wang Z, Liu Y, Xing S, et al. Preconception Thyroid Function Optimization and Pregnancy Outcomes in Women with Recurrent Pregnancy Loss: A Real-World Cohort Study Endocr Connect, 2026.PMID 42447048
11. [11]Signorelli F, de Andrade Lopes FO, Gomes ACS, Balbi GGM, et al. IgM antiphospholipid antibodies are associated with a microvascular phenotype in antiphospholipid syndrome Adv Rheumatol, 2026.PMID 42277921
12. [12]Grossi C, Bodio C, Kumar S, Bison E, et al. Correction: Anti-β2GPI IgG display a broad reactivity against different β2GPI domains beyond domain 1: results from the APS ACTION and multi-center Italian cohorts Front Immunol, 2026.PMID 42273675